Skip to main content
OpenTrials
Completed

NCT Number: NCT07138131

Impact of Omega 3 in Treatment of Inappropriate Sinus Tachycardia

This study aimed to evaluate the effect of omega-3 supplementation on heart rate (HR) control and heart rate variability (HRV) in children with inappropriate sinus tachycardia (IST).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Omega 3 Inappropriate Sinus Tachycardia Treatment

Age range

12 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Benha University

Banhā, Al-Qalyubia, 13518, Egypt

About this study

Inappropriate sinus tachycardia (IST) is a is a common disease of the autonomic nervous system in children in which tachyarrhythmia characterized by a persistent increase in resting sinus rate or disproportionate elevation of heart rate (HR) with minimal physiological effort accompanied by wide ranging symptoms including palpitations, fatigue, presyncope, and exercise intolerance it could cause lead to total disability in severe cases .it also takes a chronic course with Significant adverse effects on quality of life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 12 to 16 years.
  • Both sexes.
  • Patients diagnosed with inappropriate sinus tachycardia (IST).
  • Patients with resting heart rate (HR) ≥100 bpm (sitting) and/or 24-hour average HR ≥90.

Exclusion criteria

  • Structural heart disease.
  • Patients receiving antiarrhythmic medication.
  • Patients with a prior history of arrhythmias such as paroxysmal supraventricular tachycardia (PSVT) or sick sinus syndrome, or orthostatic hypotension.
  • Secondary conditions such as anemia, infection, or hyperthyroidism.

Treatment and study plan

OMega 3

Drug

Patients received omega-3 supplementation for 3 months.

standard follow-up

Other

Patients received standard follow-up without treatment.

Primary outcomes

  1. Heart rate

    Time frame: 24 hours post-treatment

    Heart rate was recorded at baseline and post-treatment.

Secondary outcomes

  1. Heart rate variability (HRV)

    Time frame: 24 hours post-treatment

    Heart rate variability (HRV) was recorded at baseline and post-treatment.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Aug 22, 2025
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.